Clinical Trial

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the effect on low-density lipoprotein-cholesterol (LDL-C) and the safety and tolerability of a fixed dose combination (FDC) of laroprovstat/rosuvastatin versus rosuvastatin alone in patients with hypercholesterolaemia with either a history of a clinical atherosclerotic cardiovascular disease (ASCVD) event or at increased risk for a first clinical ASCVD event.
Trial Details
NCT Number NCT07619118
Lead Sponsor AstraZeneca
Conditions Hypercholesterolaemia
Enrollment 200 participants
Start Date 2026-09-15
Primary Completion 2027-05-28 (estimated)
Study Completion 2027-05-28 (estimated)
Updated on ClinicalTrials.gov 2026-06-01